Search results for "risk of fracture"

showing 1 items of 1 documents

Early Denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: A case-control retrospective stu…

2021

BACKGROUND: Aromatase inhibitors (AIs) might have a detrimental impact on bone health in breast cancer (BC) women. Denosumab has been shown to reduce the risk of fractures, but the appropriate time for starting is yet to be clearly defined. OBJECTIVE: To evaluate the effects of early treatment with Denosumab (⩽ 12 months after starting AIs) compared to a delayed treatment in BC women. METHODS: In this retrospective case-control study, we included medical records of BC post-menopausal women, treated with AIs therapy; they were divided as: study group (starting Denosumab ⩽ 12 months after AIs) and control group (> 12 months). At the baseline (T0) and at 18 months (T1), we evaluated the lum…

Osteoporosisrisk of fracture0302 clinical medicineRetrospective StudieBone DensityOrthopedics and Sports Medicine030212 general & internal medicineAromataseOsteoporosis PostmenopausalbiologyBone Density Conservation AgentsAromatase InhibitorsSettore MED/34 - Medicina Fisica E RiabilitativaMedical recordRehabilitationMiddle Agedmedicine.anatomical_structureDenosumab030220 oncology & carcinogenesisOsteoporosis risk of fractures breast cancer denosumab bone healthFemaleDenosumabCase-Control StudieBreast NeoplasmHumanmedicine.drugmedicine.medical_specialtyBone Density Conservation AgentPhysical Therapy Sports Therapy and RehabilitationBreast NeoplasmsBone health03 medical and health sciencesbreast cancerBreast cancerInternal medicinemedicineAromatase InhibitorHumansbone healthFemoral neckAgedRetrospective Studiesrisk of fracturesbusiness.industryOsteoporosiRetrospective cohort studymedicine.diseaseCase-Control Studiesbiology.proteinbusinessOsteoporotic Fractures
researchProduct